Prognosis of glioblastoma with faint MGMT methylation-specific PCR product

摘要: Methylation-specific polymerase chain reaction (MSP) for the promoter methylation status of O6-methylguanine-DNA-methyltranferase (MGMT) gene theoretically provides a positive or negative result. However, faint MSP product is difficult to interpret. The aim this study was evaluate significance in glioblastoma (GBM). Critical concentrations methylated control DNA, i.e., 100, 1, 0.5 and 0 % were run parallel with 116 newly diagnosed GBMs order standardize interpretation distinguish (+), equivocal (±), (−; unmethylated) results. Cases its intensity between those 1 DNA controls considered (±). MGMT quantifications also determined by quantitative real-time (qMSP) pyrosequencing (PSQ), protein expression detected immunohistochemistry. There significant correlations all aforementioned studies. concordance rates MSP+ qMSP+ cases, as well MSP− qMSP− cases 100 %, MSP± comprised 76.5 23.5 cases. PSQ showed that heterogeneous more frequently encountered Multivariate analyses disclosed although overall survival indistinct from progression free significantly worse In conclusion, products should be distinguished their behaviors different.